Page last updated: 2024-08-24

topotecan and fluorouracil

topotecan has been researched along with fluorouracil in 33 studies

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (12.12)18.2507
2000's15 (45.45)29.6817
2010's12 (36.36)24.3611
2020's2 (6.06)2.80

Authors

AuthorsStudies
Chen, Y; Ding, J; Gao, H; Huang, M; Li, C; Lu, W; Shen, H; Sun, J; Zhang, X1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Amen, Y; El-Sayed, MA; Kitamura, M; Okauchi, T; Othman, DIA; Selim, KB; Shimizu, K; Tantawy, AS1
Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D1
McCann, J1
Punt, CJ1
Berger, NA; Eshleman, JR; Markowitz, SD; Yang, B1
Boisdron-Celle, M; Boulanger, N; Gamelin, E1
Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ1
Ratain, MJ1
Devereux, L; Goldberg, J; Grana, G; Hageboutros, A; Khatri, J; Rodman, WD; Sbar, EI; Tritschler, L1
Bonnar, J; Gleeson, NC; McGuinness, EP; O'Toole, SA; Sheppard, BL; Yoneda, M1
Deckert, PM; Hütter, G; Keilholz, U; Szélenyi, H; Thiel, E1
Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C1
Eklund, JW; Mulcahy, MF; Trifilio, S1
Adams, N; Barrera, D; Cunningham, C; Graham, S; Nemunaitis, J; Nugent, J; Senzer, N; Stewart, C1
de Gelder, V; De Ridder, L; De Vos, F; Lambert, B; Slegers, G; Thierens, H; Van de Wiele, C1
Chen, Z; Feng, YL; Gu, W; Li, B; Ling, CQ1
Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE1
Gmeiner, WH; Pommier, Y; Reinhold, WC1
Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D1
Francia, G; Hackl, C; Kerbel, RS; Man, S; Milsom, C; Xu, P1
Cao, KI; Kirova, YM1
Husseini, GA; Ibrahim, M; Sabouni, R1
Anderson, RG; Bischak, MM; Broskin, SA; Campbell, CA; Foltz, LE; Higby, KJ; Koper, JA; Nickle, AC; Resendes, KK1
Choi, YS; Jo, DY; Kim, JM; Ko, YB; Lee, HJ; Ryu, H; Song, IC; Yun, HJ1
Bhattacharya, A; Chintala, S; Durrani, FA; Rustum, YM1
Banerjee, S; Datta, S; Jahnavi, J; Maity, TR; Samanta, A1
Bonnabry, P; Fleury-Souverain, S; Guillarme, D; Maurin, J; Rudaz, S1

Reviews

8 review(s) available for topotecan and fluorouracil

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
New anticancer agents in clinical development.
    Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:11

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan

1995
New drugs in the treatment of colorectal carcinoma.
    Cancer, 1998, Aug-15, Volume: 83, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil

1998
[Pharmacokinetic monitoring].
    Bulletin du cancer, 2000, Volume: 87, Issue:1

    Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug Monitoring; Etoposide; Fluorouracil; Humans; Irinotecan; Liver; Paclitaxel; Topotecan

2000
Pharmacokinetically guided administration of chemotherapeutic agents.
    Clinical pharmacokinetics, 2000, Volume: 39, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Busulfan; Carboplatin; Cisplatin; Etoposide; Fluorouracil; Humans; Topotecan

2000
Chemotherapy dosing in the setting of liver dysfunction.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:8

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Liver; Liver Diseases; Liver Function Tests; Male; Maximum Tolerated Dose; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Topotecan

2005
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2014, Volume: 18, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine

2014
Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs).
    Current medicinal chemistry, 2017, Volume: 24, Issue:2

    Topics: Antineoplastic Agents; Busulfan; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Carriers; Fluorouracil; Humans; Nanoparticles; Organometallic Compounds; Organoplatinum Compounds; Polymers; Porosity; Succinates; Topotecan

2017

Trials

5 trial(s) available for topotecan and fluorouracil

ArticleYear
Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies.
    Cancer investigation, 2002, Volume: 20, Issue:5-6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan; Treatment Outcome

2002
Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Drug Resistance; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Topotecan

2004
Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients.
    The Journal of oncology management : the official journal of the American College of Oncology Administrators, 2005,Summer, Volume: 14, Issue:3

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Topotecan; Treatment Outcome

2005
[Ginsenosides and dexamethasone in managing the liver injury and renal function after transcatheter arterial chemoembolization for hepatic carcinoma patient].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:11

    Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Blood Urea Nitrogen; Chemoembolization, Therapeutic; Creatinine; Dexamethasone; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Ginsenosides; Glucocorticoids; Humans; Iodized Oil; Kidney; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Topotecan

2006
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
    Journal of neuro-oncology, 2011, Volume: 105, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Topotecan

2011

Other Studies

20 other study(ies) available for topotecan and fluorouracil

ArticleYear
Synthesis and antitumor activity of 7-ethyl-9-alkyl derivatives of camptothecin.
    Bioorganic & medicinal chemistry letters, 2005, Apr-15, Volume: 15, Issue:8

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Humans

2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
Design, Synthesis and Anticancer Evaluation of New Substituted Thiophene-Quinoline Derivatives.
    Bioorganic & medicinal chemistry, 2019, 10-01, Volume: 27, Issue:19

    Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Caspase 9; Cell Proliferation; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Molecular Structure; Quinolines; Structure-Activity Relationship; Thiophenes

2019
Colon cancer: new drug options improve on 5-FU.
    Journal of the National Cancer Institute, 1998, Jul-01, Volume: 90, Issue:13

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

1998
Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Cell Death; Colonic Neoplasms; Fluorouracil; Humans; Isopropyl Thiogalactoside; Time Factors; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Protein p53

1996
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Labeling; Female; Fluorouracil; Humans; Kidney; Male; Prodrugs; Topotecan

2002
The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours.
    Cancer detection and prevention, 2003, Volume: 27, Issue:1

    Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Endometrial Neoplasms; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Neoplasm Staging; Paclitaxel; Retrospective Studies; Tetrazolium Salts; Topotecan; Toxicity Tests; Treatment Outcome; Uterine Cervical Neoplasms

2003
Cancer cell adaptation to chemotherapy.
    BMC cancer, 2005, Jul-18, Volume: 5

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation

2005
Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma.
    Canadian journal of physiology and pharmacology, 2006, Volume: 84, Issue:10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cobalt Radioisotopes; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gamma Rays; Gemcitabine; Glucose Transporter Type 1; Humans; Rhenium; Topotecan

2006
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan

2010
Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:12

    Topics: Camptothecin; Cell Line, Tumor; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endocytosis; Floxuridine; Fluorodeoxyuridylate; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Irinotecan; MicroRNAs; National Cancer Institute (U.S.); Nucleosides; RNA, Messenger; Topoisomerase I Inhibitors; Topotecan; United States

2010
Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.
    Gut, 2013, Volume: 62, Issue:2

    Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease Models, Animal; Female; Fluorouracil; HT29 Cells; Humans; Immunohistochemistry; Injections; Leucovorin; Liver Neoplasms; Mice; Mice, SCID; Organoplatinum Compounds; Survival Rate; Topotecan

2013
5-Flurouracil disrupts nuclear export and nuclear pore permeability in a calcium dependent manner.
    Apoptosis : an international journal on programmed cell death, 2017, Volume: 22, Issue:3

    Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Camptothecin; Caspases; Cell Nucleus; DNA Topoisomerases, Type I; Drug Interactions; Egtazic Acid; Fluorouracil; HeLa Cells; Humans; Irinotecan; Neoplasm Proteins; Nuclear Pore; Permeability; ran GTP-Binding Protein; Topotecan; Tumor Suppressor Protein p53

2017
ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.
    Medicine, 2017, Volume: 96, Issue:51

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma; Cisplatin; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pelvic Neoplasms; Retrospective Studies; Survival Analysis; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms

2017
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
    International journal of molecular sciences, 2018, Oct-29, Volume: 19, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Mice, Nude; MicroRNAs; Selenocysteine; Selenomethionine; Topotecan

2018
Towards establishment of a plant-based model to assess the novel anti-cancerous lead molecule(s): An in silico, in vivo and in vitro assessment of some potential anti-cancerous drugs on Lathyrus sativus L.
    Protoplasma, 2022, Volume: 259, Issue:6

    Topics: Colchicine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; Fluorouracil; Humans; Lathyrus; Methotrexate; Pemetrexed; Plant Proteins; RNA; Topotecan

2022
Development and application of a liquid chromatography coupled to mass spectrometry method for the simultaneous determination of 23 antineoplastic drugs at trace levels.
    Journal of pharmaceutical and biomedical analysis, 2022, Nov-30, Volume: 221

    Topics: Antineoplastic Agents; Busulfan; Carboplatin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Fluorouracil; Ganciclovir; Humans; Idarubicin; Ifosfamide; Irinotecan; Methanol; Methotrexate; Oxaliplatin; Paclitaxel; Pemetrexed; Tandem Mass Spectrometry; Topotecan; Vinblastine; Vincristine; Water

2022